qPCR Reagents Market - New Growth Opportunities for Market Leaders
According to research report qPCR
reagents market is poised to reach $1,893.9 Million by 2020 From USD
1,307.0 Million in 2015, growing at a CAGR of 7.7%, during 2015 to 2020.
Over the last decade, the qPCR industry has witnessed
significant technological advancement & robust product development. These
advancements are transforming the field of forensic & disease diagnostic
application of qPCR; leading to more effective & timely treatment of
chronic and infectious diseases (such as cancer, AIDS, influenza, and
hepatitis).
North America and a major part of Europe are mature
markets for qPCR reagents. However, emerging regions such as Asia-Pacific
(including China and India) are expected to become new revenue-generating pockets
in the market over the next five years. The North American qPCR reagents market
is expected to hold the largest share during the forecast period owing to high
penetration of qPCR technologies among key end users, increasing public &
private funding to expand the application base of qPCR, ongoing product
advancements in the field of qPCR reagents, and continuous reduction in the
average cost of genome sequencing.
The Asia-Pacific region is expected to witness the fastest
market growth for qPCR reagents during the forecast period. Growth in this
market is fueled by increasing penetration of global life sciences companies in
this region, rising focus of governments on increasing the awareness about
gene-based disease diagnosis and treatment, growing public and private support
to develop novel qPCR technologies, and advancing cancer research in Japan.
Due to the significant growth opportunities offered by
emerging countries, a number of players operating in the market are focusing on
expansion in these regions. For instance, in November, 2012, Thermo Fisher
Scientific established a manufacturing facility in Suzhou (China) with an
investment of USD 20 Million. The facility is involved in the manufacturing of
life science equipment and consumables (including qPCR reagents) and caters to
the life science & pharmaceutical industry. Similarly, in August, 2012, Bio-Rad
Laboratories established the Digital Biology Center (U.S.) to develop
innovative PCR products based on the company’s droplet partitioning technology.
The qPCR reagents that are used for pathogen detection,
forensic applications, and disease diagnosis offer a promising future to market
aspirants focusing on expanding their revenue base in the market. Their growth
is propelled by the increasing R&D to develop and commercialize novel
products, growing market adoption of gene-based diagnostic techniques, and
rising emphasis on effective & early disease diagnosis across major markets.
Several companies such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories
Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and Takara
Bio are investing in these high-growth markets to gain higher profits and to increase
their shares in the global qPCR reagents market.
Comments
Post a Comment